NIMG-51. PROSPECTIVE CASE CONTROL STUDY OF HYPOXIA FMISO PET/MRI AS A DIAGNOSTIC FEATURE OF GLIOBLASTOMA IMMUNOTHERAPY FAILURE

Abstract

Abstract BACKGROUND Hypoxia is a prognostic biological feature of glioblastoma. 18F-fluoromisonidazole (FMISO) PET quantifies tumor hypoxia. Efficacy of checkpoint immunotherapy is being investigated, but specific response assessment criteria remain unknown. We hypothesized that tumor hypoxia is a defining feature of immunotherapy failure in patients with glioblastoma. METHODS A prospective case control study was undertaken in patients with newly diagnosed IDH wildtype glioblastoma (NCT03649880). Cases were concurrently enrolled in a phase II study (NCT03347617) of pembrolizumab immunotherapy (200 mg IV every 3 weeks) combined with Stupp protocol temozolomide-based chemoradiotherapy following maximal safe resection. Controls did not receive pembrolizumab. FMISO PET/MRI (3.7 MBq/kg, 90 min uptake) was performed at time of mRANO presumed progression. Hypoxic volume (HV) was defined by pixels with FMISO uptake ≥1.2x that of mean cerebellar uptake. MRI-Gd enhancing volume was segmented using a semi-automated approach. Hypoxic fraction (HF) was defined as the HV-to-MRI enhancing volume ratio. Disease progression or pseudoprogression (Psp) was confirmed through surgery or follow-up MRI. T-test and receiver operator characteristic (ROC) analysis assessed differences and diagnostic performance. RESULTS 18 patients (14 cases [11 progression and 3 Psp] and 4 controls [3 progression and 1 Psp]) provided evaluable disease. For all patients, HF was significantly elevated with progression (1.44 ± 0.8; N=14) compared to Psp (0.31 ± 0.3; N= 4; P=0.01). HV was not different (P=0.10). No difference in HV or HF was observed between Cases and Controls (P> 0.42). Use of HF yielded an AUROC of 0.96 with an optimal cut off of 0.74, to differentiate progression from Psp. CONCLUSION At mRANO presumed progression HF with FMISO PET/MRI accurately distinguishes tumor progression from neuroinflammatory Psp, irrespective of prior pembrolizumab immunotherapy. The incorporation of FMISO PET/MRI in larger prospective therapeutic clinical trials in patients with glioblastoma is underway and likely to improve response assessment criteria.